Marker for detecting immune escape of lung cancer cells and application thereof

By detecting the lactoacylation modification of the APOC2-K70 site in lung cancer cells, a marker predicting immunotherapy resistance is provided, and the use of APOC2-K70Kla antibody in combination with PD-1 antibody significantly reduces the size of lung cancer cells and Weight solves the problem of immune escape resistance of lung cancer and improves immune efficacy.

CN118994366APending Publication Date: 2024-11-22SHANGHAI SONGJIANG DISTRICT CENTRAL HOSPITAL +1
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410921037.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-10
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art is difficult to effectively predict and cope with the immune escape of lung cancer cells, especially the drug resistance problems that arise in immunotherapy. The regulatory mechanism of APOC2 in the tumor immune microenvironment is still unclear.

Method used

By detecting lactoylation modification at the APOC2-K70 site, a high sensitivity and specific biomarker APOC2-K70Kla is used to predict resistance to lung cancer immunotherapy and design specific lactoylated antibodies for use in the use of Testing and treatment.

Benefits of technology

Effectively predict the drug resistance of lung cancer immunotherapy and provide APOC2 as a molecular target for lung cancer treatment. The combined use of APOC2-K70Kla antibody and PD-1 antibody significantly reduces tumor volume and weight and improves immune efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994366A_ABST
    Figure CN118994366A_ABST
Patent Text Reader

Abstract

The invention discloses a marker for detecting immune escape of lung cancer cells and application of the marker. The marker is subjected to APOC2-K70 site milk acylation modification. The specific APOC2-K70 site lactoacylation antibody is prepared, and lactoacylation modification of the APOC2-K70 site in an immunotherapy lung cancer sample can be specifically detected, so that whether lung cancer cells tolerate immunotherapy or not can be predicted. According to the invention, APOC2-K70 lactoacylation modification is taken as a lung cancer immune tolerance detection index, and the lactoacylation antibody at the APOC2-K70 site is combined with immunotherapy, so that lung cancer cells can be effectively killed, and a new strategy is provided for precise treatment of lung cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of tumor immune escape, and in particular, to a marker for detecting immune escape of lung cancer cells and application thereof. Background Art

[0002] The combined use of immunotherapy and chemotherapy drugs has become a promising direction for tumor treatment, especially in non-small cell lung cancer. With the widespread clinical application of PD-1 / PD-L1, the survival of patients with advanced lung cancer has been extended, but many patients will experience disease progression during treatment or after treatment interruption. Among lung cancer patients who receive immunotherapy in the first-line treatment, 7%-27% of patients develop primary drug resistance, and this proportion is 20%-44% in the second-line treatment. Due to the immune microenvironment of tumor cells and the body's peripheral immunity, studying the resistance mechanism of combined therapy has become a difficult problem that needs to be overcome.

[0003] Metabolic reprogramming is a fundamental feature of cancer. In recent years, efforts have been made to study the role of metabolites and metabolic processes in the regulation of immune function. Various metabolites (such as glucose, fatty acids, and amino acids) coordinate with immune signaling pathways to control immune cell function and differentiation. Metabolic reprogramming is emerging as a new therapeutic target to enhance immune function and the outcome of immunotherapy. Even under aerobic conditions, tumor cells tend to produce a large amount of lactate through glycolysis, the so-called "Warberg effect". The large amount of lactate accumulated in tumor cells is not only absorbed and transported to the mitochondria by tumor cells for oxidation to provide energy, but also lactate can be released into the extracellular environment to promote the acidification of the tumor microenvironment. This in turn gives tumor cells some favorable properties that help them enhance their ability to survive and develop. More and more studies have found that lactate can activate many important signaling pathways in tumor cells and promote the survival, invasion, immune escape, metastasis, and angiogenesis of various types of tumors. Recently, it has been reported that in a highly glycolytic tumor microenvironment, Treg cells take up lactate through MCT1 and strongly express PD-1, resulting in impaired PD-1 blockade therapy. In addition, lactic acid is a new type of modification group that regulates histone lactylation modification and plays a role in gene transcription regulation. With the successive reports of lactylation modification enzymes and delactylation modification enzymes, the study of non-histone lactylation modification and biological functions has received extensive attention from scientists, which will open up a new field of tumor research. Discovering highly lactylated non-histone proteins in tumor cells and studying their upstream and downstream regulatory mechanisms will provide a theoretical basis for explaining the important role of lactylation, a new modification, in tumor research, and provide a new idea and molecular mechanism for tumor research.

[0004] Free fatty acids (FFAs) are extremely important energy sources for immune cells in the tumor microenvironment. They can be incorporated from the extracellular medium or obtained from the hydrolysis of triglycerides, mainly mediated by lipoprotein lipase (LPL). It has been reported that memory T (TCM) cells use intrinsic lipolysis and increased uptake of exogenous FFAs to support metabolic programs essential for development. Increased FFAs in the hypoglycemic TME of gastric cancer (GC) subpopulations support the accumulation of Treg cells and generate an immunosuppressive TME, which is the basis for resistance to immune checkpoint blockade. Therefore, inhibiting FFA production in the TME by altering immune cell function may be an attractive approach to help appropriate immunotherapy achieve maximum efficacy. LPL is mainly activated by apolipoproteins, which are the main lipoproteins involved in lipid transport, mainly expressed in liver tissue, and transported through blood vessels. Apolipoproteins in the blood transport lipids into cancer cells, providing energy for cancer cell proliferation and invasion. Apolipoproteins are also important factors in cell signaling. For example, apolipoprotein E (APOE) interacts with low-density lipoprotein receptor-related protein 1 (LRP1) and low-density lipoprotein receptor-related protein 8 (LRP8) in tumor cells to inhibit tumor cell invasion. Apolipoprotein B (APOB) inhibits angiogenesis by regulating the expression of VEGF receptors, which is a key process in tumor cell invasion and metastasis. Apolipoprotein C1 participates in maintaining pancreatic cancer cell survival by regulating cell apoptosis. Apolipoprotein C2 (APOC2) is mainly biosynthesized in the liver and intestine and exists in plasma chylomicrons, VLDL, and high-density lipoprotein (HDL). It activates lipoprotein lipase, which hydrolyzes triglycerides to provide free fatty acids to cells. Recent studies have shown that high serum APOC2 levels are associated with poor prognosis of pancreatic adenocarcinoma. High levels of APOC2 promote the growth and invasion of pancreatic cancer cells, suggesting that APOC2 has a potential carcinogenic role in tumorigenesis, but its underlying mechanism is still unclear. There is still insufficient research on the regulation of APOC2 in the tumor immune microenvironment and whether it can be used as a target for tumor immune escape detection or treatment. Therefore, it will be extremely meaningful to study the relationship and regulation of APOC2 and tumor immunity, which will be conducive to the search for predictive markers for tumor immune escape and can be actually used to predict clinical tumor prognosis and guide immunotherapy. Summary of the invention

[0005] The purpose of the present invention is to solve the problem of whether APOC2 can be used as a target for tumor immune escape detection or treatment, and to provide a biomarker with high sensitivity and specificity that can be actually applied to the prediction of lung cancer immune escape by utilizing the discovered lactylation modification of the APOC2-K70 site.

[0006] In order to achieve the above object, the present invention is implemented by the following scheme:

[0007] The present invention provides a detection method for testing the immune escape of lung cancer cells, which detects whether the APOC2-K70 site is lactylated and determines whether resistance to lung cancer immunotherapy is produced. When lactylation occurs, it indicates that the lung cancer cells are resistant to immunotherapy.

[0008] To achieve the above object, the present invention provides a marker for detecting immune escape of lung cancer cells, wherein the marker is lactylation of the APOC2-K70 site, denoted as APOC2-K70Kla.

[0009] The lung cancer immunotherapy includes PD-1, PD-L1, and CTLA4 antibody treatment.

[0010] Preferably, the lung cancer immunotherapy is PD-1 therapy.

[0011] As another aspect of the present invention, the present invention provides a lactylation antigen designed specifically for the APOC2-K70 site, wherein the lactylation antigen is a polypeptide having an amino acid sequence such as YLPAVDEKLRDLYSK.

[0012] The present invention also prepares specific lactylated antibodies against lactylated antigens at the APOC2 site.

[0013] The antibody preparation method is as follows:

[0014] Step 1: Synthesize an antigen synthetic peptide containing the APOC2-K70 lactylation site, and design a synthetic peptide of 15 amino acids on both sides of the APOC2-K70 site;

[0015] The synthesis process of the antigen synthetic peptide at the APOC2-K70 lactylation site was to add a lactylation group to the amino acid K70 and couple it with the carrier protein hemocyanin KLH to form a full antigen synthetic peptide, which was coupled with the carrier protein bovine serum albumin and used as a filler for affinity purification. All synthetic peptides were purified by HPLC and detected by mass spectrometry;

[0016] Step 2: Immunization of rabbits with full antigens and collection of antiserum: The antigen synthetic peptide containing the APOC2-K70 lactylation site in step 1 was combined with an adjuvant to immunize SFP-grade New Zealand white rabbits, and the antigen emulsion was injected into the back skin at multiple points; the number of immunizations included 3 injections and a final booster injection, and the titer of the antiserum against the target synthetic peptide was determined by ELISA;

[0017] Step 3: Purify and identify APOC2 protein K70 specific lactylated antibody, i.e. APOC2-K70Kla antibody: use affinity chromatography with synthetic peptide coupled agarose chromatography column to perform antibody affinity separation-affinity purification method; first pass through a non-lactylated synthetic peptide coupled chromatography column to remove non-lactylated antibodies in the antiserum to obtain serum containing lactylated antibodies; then pass the above serum through a lactylated synthetic peptide coupled chromatography column, and finally elute to obtain serum containing lactylated antibodies, and finally identify the titer of the antibody by Western blot experiment.

[0018] The present invention also provides a nucleic acid, which is composed of a base sequence encoding an antigenic synthetic peptide containing an APOC2-K70 lactylation site, and the base sequence thereof is shown in SEQ ID NO: 2, which is:

[0019] TACCTGCCCGCTGTAGATGAGAAAACTCAGGGACTTGTACAGCAAA.

[0020] The present invention also provides the APOC2-K70Kla antibody for use in lung cancer immune escape detection and other related tumor treatment predictions.

[0021] The present invention also provides the development of an ELISA detection kit for using the APOC2-K70Kla antibody for tumor immune escape and the like, the kit comprising: the APOC2-K70Kla antibody, a blocking solution, a secondary antibody, a color developing solution and a buffer, wherein the blocking solution is 5% BSA, the secondary antibody is an anti-rabbit secondary antibody, the color developing solution is TMD, and the buffer is PBS.

[0022] To support the purpose of the present invention, the following four aspects of research were conducted: screening of APOC2-K70Kla, preparation of APOC2-K70Kla antibodies, involvement of APOC2-K70Kla in lung cancer immune escape, and APOC2-K70Kla antibody combined with immunotherapy to kill tumors.

[0023] In a specific embodiment, the screening process of APOC2-K70Kla provided by the present invention is as follows: performing lactylomics on clinical samples of lung cancer, and finding that APOC2 is lactylated; further identifying the lactylation site of APOC2-K70 by mass spectrometry, recorded as APOC2-K70Kla; treating human lung cancer cells A549 overexpressing APOC2 with high lactic acid, and finding that the lactylation modification of APOC2 is significantly enhanced.

[0024] In another embodiment, the present invention designs a specific lactylated antigen YLPAVDEKLRDLYSK for the human APOC2-K70 site to prepare a specific lactylated antibody, verifies the specificity of the antibody, and further verifies that APOC2-K70 in cells is lactylated under high lactate treatment.

[0025] Further comparison of the conservation of APOC2-K70 in different species revealed that APOC2-K70 is an important lactylation site of APOC2 and is highly conserved among different species.

[0026] Furthermore, the APOC2-K70Kla level in patients with non-small cell lung cancer (NSCLC) resistant to immunotherapy was detected, and it was found that APOC2-K70Kla was significantly increased in the immune-resistant group. In addition, the APOC2-K70Kla level was negatively correlated with the overall survival (OS) of the patients.

[0027] Finally, mouse lung cancer cells LLC were injected into C57 mice to construct a tumor-bearing model. After the seventh day, PD-1 antibodies, APOC2-K70Kla antibodies, and LDHA inhibitor FX11 (inhibiting the lactylation modification of APOC2-K70) were injected. The results showed that compared with treatment with PD-1 antibodies alone, the tumor volume and weight were significantly reduced in combination with APOC2-K70Kla antibodies or FDX11.

[0028] Compared with the prior art, the present invention has the following beneficial effects:

[0029] (1) The present invention provides a marker for predicting lung cancer immune tolerance and its application, using the detection of whether APOC2-K70 site is lactylated as a detection index to determine whether lung cancer immune tolerance is produced;

[0030] (2) Through research and experiments, an antibody targeting the APOC2-K70 site is finally provided, which is helpful for the development of inhibitor drugs targeting APOC2-K70. The inhibitor is a small molecule compound or a polypeptide drug used to block the lactylation of the APOC2-K70 site, suggesting that APOC2 is used as a molecular target for the treatment of lung cancer; (3) The APOC2-K70Kla antibody discovered by the present invention can be combined with the PD-1 antibody to effectively treat lung cancer, which is helpful to reveal the important application value of the APOC2-K70Kla antibody in the immunotherapy of lung cancer, and also reveals that the APOC2-K70Kla antibody has broad clinical application prospects in disease diagnosis, treatment and prognosis determination. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1.Lactylated modification of APOC2 at the K70 site was identified in clinical tissue samples of lung cancer. Figure a shows the mass spectrometry identification process of clinical tissue samples; Figure b shows the identified APOC2 lactylation; Figure c shows the spectrum of APOC2-K70Kla identified by lactylated mass spectrometry.

[0032] Figure 2 APOC2-K70Kla is enhanced under lactic acid treatment. Figure a shows the lactylation changes of lung cancer cells A549 overexpressing APOC2 under lactic acid treatment; Figure b shows the lactylation changes of A549 cells overexpressing APOC2 wild type (WT) and K70 mutant form (K70R / K70Q) under lactic acid treatment.

[0033] Figure 3 . Preparation and specificity verification of specific APOC2-K70Kla antibodies. Figure a is a schematic diagram of antibody purification; Figure b is antibody specificity verification; Figure c is the APOC2-K70Kla antibody indicating changes in APOC2 under lactic acid treatment; Figure d is a comparison of conserved sequences of different species.

[0034] Figure 4 .The relationship between APOC2-K70Kla and lung cancer immune tolerance and survival. Figure a shows the relationship between APOC2-K70Kla and lung cancer immune tolerance; Figure b shows the relationship between APOC2-K70Kla and lung cancer patient survival.

[0035] Figure 5 .APOC2-K70Kla antibody can enhance the efficacy of PD-1. Figure a is a diagram of the immunotherapy model of tumor-bearing mice; Figure b is the size of the tumor in each group of mice; Figure c is the volume of the tumor in each group of mice; Figure d is the weight of the tumor in each group of mice. DETAILED DESCRIPTION

[0036] The present invention is further described in detail below in conjunction with the accompanying drawings and specific embodiments of the specification. Unless otherwise specified, the reagents and equipment used in the present invention are conventional reagents and equipment in the art. Of course, the use of instruments and materials in the embodiments is not limited to the enumeration of this example, but is based on being able to solve the technical problems of the present invention and achieve corresponding technical effects. In addition, the molecular biological methods not described in detail in the embodiments are all conventional methods in the art, and specific operations can be referred to the molecular biological guide or product instructions.

[0037] Example 1: Identification of lactylation modification of APOC2 at K70 site in clinical lung cancer tissue samples.

[0038] Figure a shows that fresh tumor tissues from lung cancer patients were used for mass spectrometry analysis by PTM Bio (Hangzhou, China). Fresh tissue samples were immediately washed with 1× PBS buffer and pulverized using Cryo-PrepTM CP02 to reduce blood protein interference. Then, they were frozen by liquid nitrogen, mixed with lysis buffer, and frozen three times on an ultrasonic processor on ice. The concentration of the extracted protein was quantified using a dithiothreitol (BCA) detection kit (Beyotime Biotech, China), and the samples were diluted to the same protein concentration. Then, they were further digested with trypsin, and the lactylated modified peptides were enriched using Pan antibody based on PTM (PTM-1404, PTM Bio) under gentle shaking at 4°C overnight. Finally, the eluted fragments were pooled and dehydrated using vacuum. The peptides were then desalted by C18 ZipTips (Millipore) for LC-MS-MS analysis. By Figure 1 In Figure b, the sites and proteins of lactylation modification can be seen from the mass spectrometry.

[0039] The mass spectrum of the lactylated APOC2 obtained in Figure b was further analyzed to obtain the mass spectrum result of APOC2-K70Kla in Figure c.

[0040] The results are as follows Figure 1 As shown in , there are a large number of lactylated proteins in lung cancer tissue samples, among which APOC2-K70 has a high abundance of lactylated modification.

[0041] Example 2: APOC2-K70Kla is enhanced under lactic acid treatment.

[0042] Flag-APOC2 was transfected into 293T cells, and 20 hours later, the cells were treated with lactate (30 mM) for 24 hours. The cells were collected, Flag was enriched with Flag-M2-beads, and the lactylation level of APOC2 was detected with a pan-lactylating antibody. Figure 2 As shown in Figure a, APOC2 undergoes obvious lactylation modification under lactic acid treatment.

[0043] The K70 site of Flag-APOC2 was mutated into the de-lactated form K70R and the simulated lactylated form K70E by site-directed mutagenesis. Then the wild-type WT and point mutant forms of Flag-APOC2 were transfected into 293T cells. After 20 hours, the cells were treated with lactate (30mM) for 24 hours, and the cells were collected. Flag was enriched with Flag-M2-beads, and the lactylation level of APOC2 was detected with a pan-lactylation antibody. Figure 2 As shown in Figure b, under lactic acid treatment, the APOC2-K70 point mutation cannot undergo lactylation modification, proving that APOC2-K70 is an important lactylation site.

[0044] Example 3: Preparation, purification, specificity and functional verification of specific APOC2-K70Kla antibody The preparation of the APOC2-K70Kla antibody comprises the following steps:

[0045] Step 1: Synthesize an antigen synthetic peptide containing the APOC2-K70 lactylation site, and design a synthetic peptide of 15 amino acids on both sides of the APOC2-K70 lactylation site, the sequence is: YLPAVDEKLRDLYSK;

[0046] The antigen synthetic peptide of APOC2-K70 lactylation site was synthesized by Shanghai Jier Biochemical Biotechnology Co., Ltd. The specific process is to add a lactylation group to amino acid K70 and couple it with the carrier protein hemocyanin KLH to form a full antigen synthetic peptide, which is coupled with the carrier protein bovine serum albumin (BSA) and used as a filler for affinity purification. All synthetic peptides were purified by HPLC and detected by mass spectrometry;

[0047] Step 2: Immunization of rabbits with full antigens and collection of antiserum: The synthetic peptide lactylated at the APOC2-K70 site in step 1 was combined with an adjuvant to immunize SFP-grade New Zealand white rabbits, and the antigen emulsion was injected into the back skin at multiple points; the number of immunizations included 3 injections and a final booster injection, and the titer of the antiserum against the target synthetic peptide was determined by ELISA;

[0048] Step 3: Purify and identify APOC2 protein K70 specific phosphorylated antibody, i.e. APOC2-K70Kla antibody: use affinity chromatography with synthetic peptide coupled agarose chromatography column to perform antibody affinity separation-affinity purification method; first pass through a non-lactylated synthetic peptide coupled chromatography column to remove non-lactylated antibodies in the antiserum to obtain serum containing lactylated antibodies; then pass the above serum through a lactylated synthetic peptide coupled chromatography column, and finally elute to obtain serum containing lactylated antibodies, and finally identify the antibody titer by Western blot experiment.

[0049] Specifically, in step 2, the whole antigen is used to prepare antiserum according to a conventional method for preparing polyclonal antibodies, including the following steps:

[0050] Preparation and purification of rabbit polyclonal antibody APOC2-K70Kla:

[0051] 1. Preparation process

[0052] 1) First dilute the antigen peptide with physiological saline, and mix the antigen peptide with the adjuvant in a ratio of 1:1 to form a stable emulsion. This operation step is completed at 4°C.

[0053] 2) Take about 1 ml of blood from the ear vein of the rabbit and obtain serum, which can be used as a negative control in the subsequent detection of antibody titer.

[0054] 3) Antigen immunization: A total of three immunizations are required:

[0055] (1) For the first immunization, 1 ml of Freund's complete adjuvant (FCA) was mixed with 100 μg of antigen dissolved in 1 ml of buffer to achieve an "oil-in-water" state and injected subcutaneously at the back spine of the rabbit 6-10 times;

[0056] (2) One week later, the second immunization was performed by thoroughly mixing 1 ml of Freund's incomplete adjuvant (FIA) with 100 μg of antigen dissolved in 1 ml of buffer and injecting it subcutaneously at the back of the rabbit (avoiding the site of the first immunization) for 6 to 10 times;

[0057] (3) One week later, the third immunization is carried out, and the operation method is the same as the second one.

[0058] 4) Heart blood sampling: After immunization, 1 ml of blood is collected from the ear vein, and serum is collected for western blot to detect antibody titer. If the titer is high, the rabbit is anesthetized and blood is collected from the heart; if the titer is not high, immunization is required again. After the rabbit is blooded from the heart, serum is collected and antibody purification is performed.

[0059] In step 3, the purification process is as follows:

[0060] 1) Prepare Sulfolink Coupling resin column

[0061] (1) Allow the Sulfolink Coupling resin and other reagents to equilibrate at room temperature for a while.

[0062] (2) Use a 1 ml pipette tip with the front end removed to draw up 2 ml of resin and place it into a dedicated filter column. Remove the plug at the bottom of the filter column to allow the liquid in the resin to flow out until 1 ml of resin solid remains.

[0063] (3) Plug the lower end of the filter column, add 4 ml of coupling buffer to the filter column to equilibrate the resin, then remove the plug at the lower end of the filter column to allow the coupling buffer to flow out. Repeat this process once and plug the lower end of the filter column.

[0064] 2) Bind the peptide or protein to the resin

[0065] (1) Dissolve 2 mg of peptide in 2 ml of coupling buffer, take out 20 μl to detect the binding efficiency, and add the rest of the liquid to the filter column.

[0066] (2) Seal the filter column from top to bottom and incubate with rotation at room temperature for 15 minutes.

[0067] (3) Remove the filter column and let it stand for 30 minutes. Open the top and bottom of the filter column to allow the liquid in the filter column to flow out. Place 20 μl of the liquid into an EP tube and mark it.

[0068] (4) Detect the absorbance of the peptide solution in step 1 and the effluent in step 3 at 280 nm, and determine the efficiency of the resin binding peptide based on the difference in the readings.

[0069] 3) Blocking non-specific binding sites on the resin

[0070] (1) Add 4 ml of Coupling Buffer to the filter column and allow it to flow out to wash the resin. Then, plug the outlet at the bottom and add an equal volume of L-Cysteine·HCl (50 mM) to the resin.

[0071] (2) Cover the filter column tightly from top to bottom and incubate with rotation at room temperature for 15 minutes.

[0072] (3) Remove the filter column and let it stand at room temperature for 30 minutes. Open the top and bottom of the filter column to allow the liquid in the filter column to flow out.

[0073] 4) Clean the filter column

[0074] (1) Add 6 ml of NaCl (1 M) to the filter column and then drain.

[0075] (2) Add 4 ml of Storage buffer to the filter column and then flow out.

[0076] (3) Soak in Storage buffer for a while and store at 4°C.

[0077] 5) Affinity purification of antibodies

[0078] Preparation of reagents

[0079] Binding / Wash Buffer: PBS, 1M NaCl

[0080] Elution Buffer: 0.1M-0.2M Glycine·HCl (PH 2.5-4.0)

[0081] Neutralization Buffer: 1M Tris·HCl

[0082] (1) Prepare the column: Equilibrate the affinity filter column to room temperature, remove the upper and lower stoppers, allow the Storage Solution in the filter column to flow out, add 6 ml of Binding Buffer to the filter column, and then let it flow out.

[0083] (2) Remove the components in the serum that are not bound to the resin: Add 5 ml of serum sample to the filter column, plug the upper and lower stoppers, and incubate with rotation at 4°C for 2-12 hours. Then remove the filter column, remove the upper and lower stoppers, allow the liquid to flow out, collect the sample, add 0.05% NaN3 to the sample, store it at 4°C, and rinse the filter column with PBS.

[0084] (3) Elute non-specific impurities bound to the resin: Add 500 μl of Glycine (PH-4) to the filter column, then remove the stopper and allow the liquid to flow out naturally. Collect the liquid with an EP tube. Repeat three times, one tube at a time. Place on ice. Then add 100 μl of Tris·HCl to each tube to neutralize the acidity of the eluate for easy storage.

[0085] (4) Elution of target protein: Use Glycine-HCI (PH-2.5) to elute the filter column, collecting the solution into an EP tube each time. Repeat 7 times, and the target protein will be eluted.

[0086] (5) Detection of concentration: Detect the absorbance of the liquid in each EP tube at a wavelength of 280 nm.

[0087] (6) Detection of IgG: Take out 10 μl from each tube and add 10 μl of 2×SDS loading to make a protein sample. Load the sample, perform electrophoresis, and stain with Coomassie Brilliant Blue. If there are clear bands at 55KD and 25KD, it means that we have bound the IgG in the serum and eluted it successfully.

[0088] (7) Dialysis: Based on the absorbance value at 280 nm and the staining result of Coomassie Brilliant Blue, select one or more tubes of liquid with the highest titer and dialyze with PBS buffer.

[0089] In step 3, the specificity and potency of the purified antibody are verified:

[0090] ELISA was used to test the titer of APOC2-K70Kla antibody. The results were as follows Figure 3 As shown in Figure a, the peptide (C-YLPAVDEK(lactyl)LRDLYSK) coated with APOC2-K70Kla has a good titer.

[0091] Flag-APOC2-WT and Flag-APOC2-K70A were transfected into 293T cells. After 20 hours, the cells were treated with lactate (30 mM) for 24 hours. The cells were collected and Flag was enriched with Flag-M2-beads. The antibody specificity was verified with anti-APOC2-K70Kla antibody. The results are shown in Figure 3 As shown in Figure c, the APOC2-K70Kla antibody has very good specificity and high titer.

[0092] Figure d. Comparison of the conservation of APOC2-K70 and its surrounding amino acid sequences in different species. Figure 3 As shown in Figure d, the APOC-K70 site is highly conserved among different species.

[0093] Results In summary, the APOC2-K70Kla antibody has very good specificity. Under lactic acid treatment, the lactylation level of APOC2 increased significantly, indicating that APOC2-K70 is an important lactylation site of APOC2 in a high lactic acid environment.

[0094] Example 4: APOC2-K70Kla antibody marks immune tolerance of lung cancer cells.

[0095] In clinical tissue samples of lung cancer with immune tolerance and intolerance, immunohistochemical analysis was performed using APOC2-K70Kla antibody, and the number of samples expressing APOC2-K70Kla antibody was counted. The results are as follows: Figure 4 As shown in Figure a, APOC2-K70Kla antibodies are positively correlated with immune tolerance.

[0096] The overall survival Kaplan-Meier curve of the non-small cell lung cancer (NSCLC) cohort was drawn according to the low and high scores of APOC2-K70Kla levels. Figure 4 As shown in Figure b, APOC2-K70Kla expression was negatively correlated with the survival of lung cancer patients.

[0097] The above results indicate that APOC2-K70Kla is positively correlated with immune tolerance in lung cancer and can be used as a marker of immune tolerance.

[0098] Example 5: The immunotherapeutic effect of APOC2-K70Kla antibody on PD-1.

[0099] like Figure 5As shown in Figure a, after LLC cells were subcutaneously injected into C57BL / 6 mice on day 0, mice were treated with short-term in vivo treatment with anti-isotype IgG, anti-PD-1, or anti-APOC2-K70Kla+anti-PD-1 or FX11+anti-PD-1. Each group received treatment with isotype control or anti-PD-1 mAb or anti-PD-1 mAb+anti-APOC2-K70Kla antibody on days 7, 9, 11, and 13 (four times), and some groups received FX11 treatment every day starting on day 7. Mice were analyzed on day 17, as shown in Figure 2. Figure 5 As shown in the middle figure b, the transplanted tumor cells were collected and photographed, and the average tumor weight (c) and volume (d) were detected and quantified. The results showed that the injection of antibody APOC2-K70Kla combined with PD-1 significantly reduced the tumor size.

[0100] The results showed that APOC2-K70Kla antibody significantly enhanced the immune efficacy of PD-1.

[0101] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A marker for detecting immune escape of lung cancer cells, characterized in that: The marker is APOC2-K70 site lactylation modification.

2. A marker for detecting immune escape of lung cancer cells according to claim 1, characterized in that: Lung cancer immunotherapy includes any of the PD-1, PD-L1, and CTLA4 antibody therapies.

3. A marker for detecting immune escape of lung cancer cells according to claim 1, characterized in that: The immunotherapy method for lung cancer is PD-1 antibody therapy.

4. A lactylated antigen, characterized in that The invention is an antigen against the marker according to claim 1, wherein the lactylated antigen is a polypeptide having an amino acid sequence as shown in SEQ ID NO:

1.

5. An antibody against a lactoylated antigen according to claim 4, characterized in that: The antibody preparation method is as follows: Step 1: Synthesize an antigen synthetic peptide containing the APOC2-K70 lactylation site, and design a synthetic peptide of 15 amino acids on both sides of the APOC2-K70 site; Step 2: Immunize rabbits with full antigens and collect antiserum: The antigen synthetic peptides in step 1 are combined with adjuvants to immunize SFP-grade New Zealand white rabbits by multiple injections in the back skin; Step 3: Purify and identify APOC2-K70Kla antibodies: Use affinity chromatography with synthetic peptide-coupled agarose chromatography columns to perform antibody affinity separation-affinity purification methods; first pass the serum through a non-lactylating synthetic peptide-coupled chromatography column to remove non-lactylating antibodies in the antiserum to obtain serum containing lactylated antibodies; then pass the serum through a lactylated synthetic peptide-coupled chromatography column, and finally elute to obtain serum containing lactylated antibodies, and finally identify the antibody titer through a Western blot experiment.

6. A nucleic acid, characterized in that Encoding the lactoylated antigen according to claim 4, the base sequence of the nucleic acid is shown in SEQ ID NO:

2.

7. The use of the antibody according to claim 5, characterized in that: Used to prepare a lung cancer immune escape detection kit.

8. A detection kit for tumor immune escape, characterized in that: The kit comprises the antibody of claim 5.

9. An ELISA detection kit for tumor immune escape according to claim 8, characterized in that: The method also comprises a blocking solution, a secondary antibody, a color developing solution and a buffer solution, wherein the blocking solution is 5% BSA, the secondary antibody is an anti-rabbit secondary antibody, the color developing solution is TMD, and the buffer solution is PBS.

10. An inhibitor drug, characterized in that Targeting APOC2-K70 site lactoylation.

Citation Information

Cited By

  • Application of marker detection reagent in preparation of product for predicting prognosis of breast cancer patient

    CN120214316A

  • Use of reagents for detecting markers in the manufacture of a product for predicting the prognosis of a breast cancer patient

    CN120214316B